Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CPHI
Upturn stock ratingUpturn stock rating

China Pharma Holdings Inc (CPHI)

Upturn stock ratingUpturn stock rating
$1.63
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

04/22/2025: CPHI (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -79.17%
Avg. Invested days 16
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 04/22/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 5.38M USD
Price to earnings Ratio -
1Y Target Price 3
Price to earnings Ratio -
1Y Target Price 3
Volume (30-day avg) 103575
Beta 0.77
52 Weeks Range 1.20 - 4.10
Updated Date 04/25/2025
52 Weeks Range 1.20 - 4.10
Updated Date 04/25/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.87

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -104.58%
Operating Margin (TTM) -105.47%

Management Effectiveness

Return on Assets (TTM) -18.29%
Return on Equity (TTM) -62.31%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 8341668
Price to Sales(TTM) 1.19
Enterprise Value 8341668
Price to Sales(TTM) 1.19
Enterprise Value to Revenue 1.84
Enterprise Value to EBITDA -225.89
Shares Outstanding 3261910
Shares Floating 2640517
Shares Outstanding 3261910
Shares Floating 2640517
Percent Insiders 30.26
Percent Institutions 0.53

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

China Pharma Holdings Inc

stock logo

Company Overview

overview logo History and Background

China Pharma Holdings, Inc. was founded in 1993. It's a specialty pharmaceutical company in China focusing on research, development, manufacture, and commercialization of pharmaceutical products.

business area logo Core Business Areas

  • Pharmaceutical Products: Development, manufacture, and commercialization of prescription and OTC pharmaceutical products in therapeutic areas such as cardiovascular, cerebrovascular, and respiratory.

leadership logo Leadership and Structure

Information on China Pharma Holdings' leadership team and organizational structure is limited in readily available public sources.

Top Products and Market Share

overview logo Key Offerings

  • Product Name 1: Cardiovascular drugs: Specific names are unavailable; market share data not publicly available. Competitors are other pharmaceutical companies manufacturing cardiovascular medications in China.
  • Product Name 2: Cerebrovascular drugs: Specific names are unavailable; market share data not publicly available. Competitors are other pharmaceutical companies manufacturing cerebrovascular medications in China.
  • Product Name 3: Respiratory drugs: Specific names are unavailable; market share data not publicly available. Competitors are other pharmaceutical companies manufacturing respiratory medications in China.

Market Dynamics

industry overview logo Industry Overview

The Chinese pharmaceutical market is large and growing, driven by an aging population, increasing healthcare expenditure, and expanding health insurance coverage. However, it is also highly competitive and regulated.

Positioning

China Pharma Holdings is a smaller player in a large and competitive market. Its competitive advantages are dependent on its product portfolio and distribution network.

Total Addressable Market (TAM)

The Chinese pharmaceutical market is estimated at hundreds of billions of dollars. China Pharma Holdings' TAM is a portion of this, determined by their product focus. Exact figures depend on products and market share in sub-segments

Upturn SWOT Analysis

Strengths

  • Established presence in China
  • Experience in pharmaceutical development
  • Distribution network in China

Weaknesses

  • Small market share
  • Limited financial resources
  • Dependence on regulatory approvals
  • Lack of detailed public financial information in English

Opportunities

  • Growing Chinese pharmaceutical market
  • Increasing demand for healthcare products
  • Potential for new product development
  • Partnerships with international pharmaceutical companies

Threats

  • Intense competition
  • Stringent regulations
  • Price pressures
  • Currency fluctuations

Competitors and Market Share

competitor logo Key Competitors

  • Unable to find information on US ticker symboled competitors for China Pharma Holdings. Competitors reside in China.

Competitive Landscape

China Pharma Holdings faces significant competition in the Chinese pharmaceutical market. Assessing its advantages and disadvantages requires more detailed information on its specific products, market share, and financial performance, which is not publicly available.

Major Acquisitions

Growth Trajectory and Initiatives

Historical Growth: Unable to determine historical growth due to limited data.

Future Projections: Unable to provide future projections due to limited analyst coverage.

Recent Initiatives: Information on recent strategic initiatives is limited in readily available public sources.

Summary

China Pharma Holdings is a small player in the competitive Chinese pharmaceutical market. Its strengths lie in its established presence and experience, but it faces challenges due to its limited resources and competitive pressures. Opportunities exist in the growing market, but success depends on navigating regulatory hurdles and securing a larger market share. Due to data limitations, a comprehensive analysis is difficult to perform.

Similar Companies

Sources and Disclaimers

Data Sources:

  • Publicly available news articles, company press releases, SEC filings (limited), and general industry reports.

Disclaimers:

The information provided is based on limited publicly available data and may not be entirely accurate or complete. This analysis is not financial advice, and investment decisions should be made based on thorough research and consultation with a financial professional.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About China Pharma Holdings Inc

Exchange NYSE MKT
Headquaters -
IPO Launch date 2002-04-17
President, CEO, Chairman & Interim CFO Ms. Zhilin Li
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 224
Full time employees 224

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​